English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Results 47 patients (59% female) had a total of 71 joints injected. Pain and reduced jaw opening were the most common preceding symptoms. Mean age at JIA diagnosis was 9.3 years, and at time of TMJ injection was 12.8. Mean time between JIA diagnosis and first TMJ injection ranged from 0.9-14.5years. JIA subtypes were: oligoarticular (18.6%), extended-oligoarticular (16.5%), polyarticular (37.2%), enthesitis-related (9.3%), and psoriatic (18.6%). At the time of TMJ injection 18 patients were receiving methotrexate, 4 prednisolone, 1 etanercept and 1 leflunomide. 3 months after TMJ injection, 51% had complete resolution of symptoms, 44% had improved and 5% had no response. 36 patients had follow-up data at a mean of 2.5 years, showing complete resolution of symptoms in 29/36 (80.5%), improvement in 3/36 (8.3%) and no improvement in 4/36 (11.2%). No cases of micrognathia, Cushing’s syndrome, or subcutaneous atrophy were documented.

Outcomes following corticosteroid injection for temporomandibular joint arthritis in juvenile idiopathis arthritis